Key result
Invalidation of the PAR2 gene impaired the kidney's ability to control sodium and potassium balance, promoting hypotension and hypokalemia in response to depletion.
Why the study?
Does PAR2 gene invalidation affect blood pressure and plasma potassium levels in response to Na(+) and K(+) depletion?
Does PAR2 gene invalidation affect blood pressure and plasma potassium levels in response to Na(+) and K(+) depletion?
PAR2 acts as an aldosterone-independent modulator of blood pressure and plasma potassium by controlling sodium reabsorption and potassium secretion in the late distal tubule.
Should not change clinical practice; leaves open PAR2 as modulator of human Na/K balance in depletion states.
Proteinase-activated receptor 2 (PAR2) is a G protein-coupled membrane receptor that is activated upon cleavage of its extracellular N-terminal domain by trypsin and related proteases. PAR2 is expressed in kidney collecting ducts, a main site of control of Na(+) and K(+) homeostasis, but its function remains unknown. We evaluated whether and how PAR2 might control electrolyte transport in collecting ducts, and thereby participate in the regulation of blood pressure and plasma K(+) concentration. PAR2 is expressed at the basolateral border of principal and intercalated cells of the collecting duct where it inhibits K(+) secretion and stimulates Na(+) reabsorption, respectively. Invalidation of PAR2 gene impairs the ability of the kidney to control Na(+) and K(+) balance and promotes hypotension and hypokalemia in response to Na(+) and K(+) depletion, respectively. This study not only reveals a new role of proteases in the control of blood pressure and plasma potassium level, but it also identifies a second membrane receptor, after angiotensin 2 receptor, that differentially controls sodium reabsorption and potassium secretion in the late distal tubule. Conversely to angiotensin 2 receptor, PAR2 is involved in the regulation of sodium and potassium balance in the context of either stimulation or nonstimulation of the renin/angiotensin/aldosterone system. Therefore PAR2 appears not only as a new actor of the aldosterone paradox, but also as an aldosterone-independent modulator of blood pressure and plasma potassium.
No takes yet. Share an insight, caveat, or question.
Morla et al. (2013) studied Blood pressure and plasma potassium regulation. Invalidation of PAR2 gene vs. Intact PAR2 gene was evaluated on Na(+) and K(+) balance, blood pressure, and plasma K(+) concentration. Invalidation of the PAR2 gene impaired the kidney's ability to control sodium and potassium balance, promoting hypotension and hypokalemia in response to depletion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: